Savitha M. Rao

Array ( [id] => 15083349 [patent_doc_number] => 20190336485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => Azophenols as ERG Oncogene Inhibitors [patent_app_type] => utility [patent_app_number] => 16/277410 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16277410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435349 [patent_doc_number] => 20190175546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS [patent_app_type] => utility [patent_app_number] => 16/273987 [patent_app_country] => US [patent_app_date] => 2019-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16273987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14403917 [patent_doc_number] => 20190167802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID [patent_app_type] => utility [patent_app_number] => 16/272713 [patent_app_country] => US [patent_app_date] => 2019-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 277 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16272713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14682453 [patent_doc_number] => 20190240341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => Preventing Central Nervous System Induced Nausea Through Use Of Vitamin B12 Conjugation [patent_app_type] => utility [patent_app_number] => 16/267883 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868414 [patent_doc_number] => 20210161881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES [patent_app_type] => utility [patent_app_number] => 16/967115 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16967115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956044 [patent_doc_number] => 11059886 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-07-13 [patent_title] => Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators [patent_app_type] => utility [patent_app_number] => 16/262711 [patent_app_country] => US [patent_app_date] => 2019-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40092 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16262711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956044 [patent_doc_number] => 11059886 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-07-13 [patent_title] => Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators [patent_app_type] => utility [patent_app_number] => 16/262711 [patent_app_country] => US [patent_app_date] => 2019-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40092 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16262711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16138951 [patent_doc_number] => 10702529 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Compositions and methods for treating insomnia [patent_app_type] => utility [patent_app_number] => 16/255116 [patent_app_country] => US [patent_app_date] => 2019-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 20466 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16255116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16040941 [patent_doc_number] => 10682321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-16 [patent_title] => Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis [patent_app_type] => utility [patent_app_number] => 16/246231 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5452 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16246231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306187 [patent_doc_number] => 20190142797 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => ENALAPRIL FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/242898 [patent_app_country] => US [patent_app_date] => 2019-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16242898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14338671 [patent_doc_number] => 20190151308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS [patent_app_type] => utility [patent_app_number] => 16/242315 [patent_app_country] => US [patent_app_date] => 2019-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16242315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206023 [patent_doc_number] => 20190365698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => Use of Antineoplastic Agents to Stimulate the Immune System for Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 16/239530 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58855 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14273361 [patent_doc_number] => 20190133965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => PHYTOTERPENOID FACILITATION OF THERAPEUTIC ONSET AND EFFICACY [patent_app_type] => utility [patent_app_number] => 16/240475 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16240475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671200 [patent_doc_number] => 20210059963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => Beta-blockers for treating and/or preventing pathological scars [patent_app_type] => utility [patent_app_number] => 16/958560 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17405997 [patent_doc_number] => 11246857 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Anti-fungal inhibitors [patent_app_type] => utility [patent_app_number] => 16/954004 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 10091 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15946011 [patent_doc_number] => 10660883 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-26 [patent_title] => Inhalable nicotine formulations, and methods of making and using thereof [patent_app_type] => utility [patent_app_number] => 16/214754 [patent_app_country] => US [patent_app_date] => 2018-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12206 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16214754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14338699 [patent_doc_number] => 20190151322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/199818 [patent_app_country] => US [patent_app_date] => 2018-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16199818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929703 [patent_doc_number] => 20190300489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => Prevention and treatment of human metabolic syndrome including type 2 diabetes, steatohepititis and related conditions using non-absorbable, orally administered compounds [patent_app_type] => utility [patent_app_number] => 16/341523 [patent_app_country] => US [patent_app_date] => 2018-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435586 [patent_doc_number] => 20200352911 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => CO-THERAPIES INCLUDING A METASTASIS INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/766156 [patent_app_country] => US [patent_app_date] => 2018-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16766156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15393847 [patent_doc_number] => 10537560 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-21 [patent_title] => P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD [patent_app_type] => utility [patent_app_number] => 16/195361 [patent_app_country] => US [patent_app_date] => 2018-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 32 [patent_no_of_words] => 51420 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16195361 [rel_patent_id] =>[rel_patent_doc_number] =>)